Please ensure Javascript is enabled for purposes of website accessibility

The Reason Behind Alere Inc.'s Double-Digit Percentage Gain on Friday

By Sean Williams - Jul 15, 2016 at 5:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The smoke is beginning to clear, and one Wall Street investment bank likes what it sees.


Image source: Getty Images.

What: Shares of Alere (NYSE: ALR), a provider of point-of-care and in-home medical diagnostic tests, surged as much as 12% during Friday's afternoon trading session. The culprit behind the move appears to be positive commentary from global investment banking firm Canaccord Genuity.

So what: As a bit of a refresher, it was announced at the beginning of February that Abbott Laboratories (ABT 1.77%) was going to buy Alere for $5.8 billion in an all-cash deal. The deal valued Alere at $56 per share, or a 51% premium to the company's valuation based on its prior-day close. Point-of-care testing is one of the fastest-growing segments within diagnostics, and the purchase was expected to broaden Abbott's product portfolio, and be immediately accretive to its earnings.

However, less than four weeks after announcing the buyout, Alere wound up delaying the filing of its annual report for fiscal 2015. It noted, at the time, that it was analyzing how revenue from Africa and China was being recognized, and trying to determine if there would be any ramifications to its previously reported results if it found something amiss. This delay in filing its results caused Abbott to request a termination of its deal to buy Alere, which Alere's board of directors promptly rejected.

Alere Afinion AS100 Analyzer. Image source: Alere.

On Thursday, July 14, Alere announced that it would have to revise its fiscal 2013, 2014, and 2015 earnings after conducting its analysis, but that it doesn't expect the changes to be material. It still hasn't filed its annual report, but the company did issue preliminary results for 2015 and the first-quarter of 2016.

Following the release of this information, Canaccord Genuity covering analyst Mark Massaro upgraded Alere to buy from hold, and announced in a note that he and his investment firm felt increasingly confident that the buyout would now go through.

Now what: Trying to play the arbitrage game is always a bit of a risk, because there's always the chance a deal could fall through. However, over the long term, Alere looks to be set up for steady growth given the rise of personalized medicine, and the growing ease-of-access to point-of-care and in-home diagnostics. Wall Street reflects this growth by forecasting that its full-year earnings will grow from the $1.90 it reported in 2014 -- which could be adjusted nominally per its announcement -- to an estimated $3.27 by 2018. All the while, revenue is expected to grow by the mid-single digits.

Assuming there are no more crippling surprises to come on the earnings-revision front, Alere should be in pretty good shape over the long term, and would thusly be priced quite attractively, even after today's romp higher, whether or not the buyout goes through.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$109.88 (1.77%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.